ArticleThe New England journal of medicine2020
Remdesivir - An Important First Step.
Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives.Drug design, development and therapy · 2026Review
- Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization.BMC infectious diseases · 2025Observational
- Impact of Remdesivir on inflammatory and prognostic markers of COVID-19: Findings of an event-monitoring study.Journal of family medicine and primary care · 2023Article
- Changes in Lymphocyte Subpopulations after Remdesivir Therapy for COVID-19: A Brief Report.International journal of molecular sciences · 2023Article
- Management of Severe and Critical COVID-19 Infection with Immunotherapies.Infectious disease clinics of North America · 2022Review
- The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2022Observational
- Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition.European journal of medicinal chemistry · 2022Article
- Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry · 2022Review
- BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review.Clinical immunology (Orlando, Fla.) · 2021Article
- Cyclodextrins in the antiviral therapy.Journal of drug delivery science and technology · 2021Review
- Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.JAMA network open · 2021Article
- Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications.Cardiovascular diagnosis and therapy · 2021Review
- In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (MMolecules (Basel, Switzerland) · 2021Article
- Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.Leukemia · 2021Observational
- BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review.Research square · 2021Article
- Adjunctive Nutraceutical Therapies for COVID-19.International journal of molecular sciences · 2021Review
- Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase.ACS central science · 2021Article
- Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.Frontiers in immunology · 2021Article
- Severe COVID-19: A distinct entity.Journal of family medicine and primary care · 2021Review
- Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey.Cardio-oncology (London, England) · 2020Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.